Variables | No. of patients | Univariate analysis | Multivariate analysis | |
---|---|---|---|---|
P-value | Relative risk (CI) | P-value | ||
Age | ||||
≥ 62 | 20 | 0.2070 | ||
< 62 | 20 | |||
Sex | ||||
Male | 26 | 0.7584 | ||
Female | 14 | |||
Primary lesion-related factors | ||||
Tumor differentiation | ||||
Well-differentiated | 18 | 0.2617 | ||
Others | 17 | |||
Tumor depth | ||||
-MP | 9 | 0.6736 | ||
SS(A)- | 31 | |||
TNM stage | ||||
I/II | 21 | 0.4869 | ||
III/IV | 18 | |||
Venous invasion | ||||
(−) | 13 | 0.3436 | ||
(+) | 21 | |||
Lymph node metastasis | ||||
(−) | 26 | 0.4522 | ||
(+) | 13 | |||
Lymphatic invasion | ||||
(−) | 7 | 0.5315 | ||
(+) | 27 | |||
Locally recurrent lesion-related factors | ||||
Tumor size (maximal diameter) | ||||
< 34 mm | 19 | 0.1067 | ||
≥ 34 mm | 19 | |||
CEA Pre-CRT | ||||
< 5 ng/ml | 15 | 0.7853 | ||
≥ 5 (ng/ml) | 25 | |||
CEA Post-CRT | ||||
< 5 (ng/ml) | 26 | 0.8175 | ||
≥ 5 (ng/ml) | 14 | |||
Resection status | ||||
R0 | 36 | 0.0299 | 0.433 (0.108–1.729) | 0.2359 |
R1 | 4 | |||
Pathologic tumor response | ||||
Responders (TRG1–TRG2) | 17 | 0.0601 | ||
Nonresponders (TRG3–TRG5) | 23 | |||
Pre-SUV | ||||
Low | 20 | 0.5475 | ||
High | 20 | |||
Post-SUV | ||||
Low | 20 | 0.0102 | 0.383 (0.104–0.940) | 0.0383 |
High | 20 | |||
∆SUV | ||||
Low | 20 | 0.9160 | ||
High | 20 | |||
DR | ||||
Low | 20 | 0.0488 | ||
High | 20 |